DISCOUNT-ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 08:45:35 03/06/2024 BST | ||
| 36.49 EUR | +0.41% |
|
| 1 month | -7.72% | ||
| 3 months | -13.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 36.49 | +0.41% |
| 31/05/24 | 36.34 | +1.34% |
| 30/05/24 | 35.86 | -0.53% |
| 29/05/24 | 36.05 | +0.59% |
| 28/05/24 | 35.84 | -2.61% |
Real-time BOERSE MUENCHEN
Last update June 03, 2024 at 08:45 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC8REC |
| ISIN | DE000HC8REC3 |
| Date issued | 16/08/2023 |
| Maturity | 20/12/2024 (201 Days) |
| Parity | 1 : 1 |
| Emission price | 42.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 43.96 € |
|---|---|
| Lowest since issue | 35.58 € |
| Spread | 0.05 € |
| Spread % | 0.14% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat